In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported

Tauangtham AnekpuritanangMatthew M. KlairmontJoel GradowskiKohei HagiwaraNathanael G. BaileyPranil ChandraYiwei LiuHeather L. MulderJohn EastonJinghui ZhangMichael G. MartinAnna B. OwczarczykJennifer B. DunlapGuang FanRichard D. PressPhilipp W. RaessSiriraj HospitalUniversity of Michigan Medical SchoolOHSU School of MedicineSt. Jude Children's Research HospitalOregon Health & Science UniversityUniversity of Tennessee Health Science CenterUniversity of Pittsburgh School of MedicinePathGroup2022-08-042022-08-042021-12-14Blood Advances. Vol.5, (2021), 5057-505924739537247395292-s2.0-85121731933https://repository.li.mahidol.ac.th/handle/20.500.14594/77401Mahidol UniversityMedicineIn a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reportedLetterSCOPUS10.1182/bloodadvances.2021004983